Core Insights - Galmed Pharmaceuticals announced significant top-line results from its AM-001 Study, a Phase 1 Bioavailability Study of Aramchol meglumine, indicating a notable improvement in bioavailability compared to Aramchol free acid tablets [1] Group 1: Bioavailability Results - The bioavailability of Aramchol meglumine 400mg granules is 5-fold greater than that of the Aramchol free acid 300mg tablets [1] - The bioavailability of Aramchol meglumine 200mg granules is 3-fold greater than that of the Aramchol free acid 300mg tablets [1] Group 2: Therapeutic Implications - The new pharmacokinetic profile allows for a once daily therapeutic regimen, which may enhance long-term adherence to the treatment [1] - The expected improvement in adherence is anticipated to significantly reduce the drug cost of goods [1]

As filed with the Securities and Exchange Commission on July 13, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) State of Israel 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 2 As filed with the Securities and Exchange Commission on July 12, 2023. Registration No. 333-272722 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) State of Israel 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide ...